DOCSLIB.ORG

Family Planning (Birth Control) By: Phd. Nuha Al-Wendawi 2018-2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Family Planning (Birth Control) By: Phd. Nuha Al-Wendawi 2018-2019 Family planning (Birth control) By: phD. Nuha Al-Wendawi 2018-2019 Maternal and Neonate Nursing Department b Objectives: To help the students identify methods of birth control and its benefits. Introduction There are a number of methods available to help prevent pregnancy, with some of the most popular including condoms and birth control pills. Deciding which method is right can be tough because there are many issues to consider, including costs, future pregnancy plans, side effects, and others. Family planning allows people to attain their desired number of children and determine the spacing of pregnancies. Benefits of family planning / contraception Promotion of family planning – and ensuring access to preferred contraceptive methods for women and couples . Contraceptive methods / Modern methods Effectiveness How it Method Description to prevent Comments works pregnancy Prevents >99% with Combined Contains two the release correct and Reduces risk oral hormones of eggs consistent use of endometrial contraceptives (estrogen and from the and ovarian (COCs) or 92% as progestogen) ovaries cancer “the pill” commonly (ovulation) used 99% with Thickens Can be used Progestogen- Contains only correct and cervical while only pills progestogen consistent use mucous to breastfeeding; Effectiveness How it Method Description to prevent Comments works pregnancy (POPs) or hormone, not block must be taken "the minipill" estrogen sperm and at the same egg from 90–97% as time each day meeting commonly and used prevents ovulation Health-care provider must Thickens Small, insert and cervical flexible rods remove; can mucous to or capsules be used for 3– block placed under 5 years sperm and Implants the skin of the >99% depending on egg from upper arm; implant; meeting contains irregular and progestogen vaginal prevents hormone only bleeding ovulation common but not harmful Thickens >99% with Delayed return cervical correct and to fertility Injected into mucous to consistent use (about 1–4 the muscle or block months on the Progestogen under the skin sperm and average) after only every 2 or 3 egg from use; irregular injectables months, 97% as meeting vaginal depending on commonly and bleeding product used prevents common, but ovulation not harmful Monthly Injected Prevents >99% with Irregular injectables or monthly into the release correct and vaginal combined the muscle, of eggs consistent use bleeding Effectiveness How it Method Description to prevent Comments works pregnancy injectable contains from the 97% as common, but contraceptives estrogen and ovaries commonly not harmful (CIC) progestogen (ovulation) used Longer and heavier Small flexible Copper periods during plastic device component first months of Intrauterine containing damages use are device (IUD): copper sperm and >99% common but copper sleeves or prevents it not harmful; containing wire that is from can also be inserted into meeting the used as the uterus egg emergency contraception Decreases amount of blood lost with A T-shaped menstruation plastic device Thickens over time; inserted into cervical Reduces Intrauterine the uterus that mucous to menstrual device (IUD) steadily block >99% cramps and levonorgestrel releases small sperm and symptoms of amounts of egg from endometriosis; levonorgestrel meeting amenorrhea each day (no menstrual bleeding) in a group of users Effectiveness How it Method Description to prevent Comments works pregnancy Forms a 98% with Also protects Sheaths or barrier to correct and against coverings that Male prevent consistent use sexually fit over a condoms sperm and transmitted man's erect 85% as egg from infections, penis commonly meeting used including HIV Sheaths, or 90% with linings, that correct and fit loosely Forms a consistent use Also protects inside a barrier to against Female woman's prevent sexually condoms vagina, made sperm and 79% as transmitted of thin, egg from commonly infections, transparent, meeting used including HIV soft plastic film >99% after 3 3 months months semen delay in taking Permanent evaluation effect while contraception stored sperm Keeps to block or cut is still present; Male sperm out the vas does not affect sterilization of deferens tubes male sexual (vasectomy) ejaculated 97–98% with that carry performance; semen no semen sperm from evaluation voluntary and the testicles informed choice is essential Permanent Eggs are Female Voluntary and contraception blocked sterilization informed to block or cut from >99% (tubal choice is the fallopian meeting ligation) essential tubes sperm Effectiveness How it Method Description to prevent Comments works pregnancy Temporary 99% with contraception correct and for new consistent use mothers whose A temporary monthly Prevents family Lactational bleeding has the release planning amenorrhea not returned; of eggs method based method requires from the 98% as on the natural (LAM) exclusive or ovaries effect of commonly full (ovulation) used breastfeeding breastfeeding on fertility day and night of an infant less than 6 months old If all 100 Emergency women used contraception Pills taken to progestin- Does not pills prevent only disrupt an (ulipristal pregnancy up Delays emergency already acetate 30 mg to 5 days after ovulation contraception, existing or unprotected one would pregnancy levonorgestrel sex likely become 1.5 mg) pregnant. Can be used to Women track Prevents identify fertile their fertile pregnancy days by both periods by avoiding Standard 95% with women who (usually days unprotected Days Method consistent and want to 8 to 19 of vaginal sex or SDM correct use. become each 26 to 32 during pregnant and day cycle) most fertile women who using cycle days. want to avoid Effectiveness How it Method Description to prevent Comments works pregnancy beads or other pregnancy. aids Correct, consistent use requires partner cooperation. 88% with common use (Arevalo et al 2002) 99% effective If the BBT has with correct risen and has Woman takes and consistent stayed higher her body use. for 3 full days, temperature at Prevents ovulation has the same time pregnancy Basal Body 75% with occurred and each morning by avoiding Temperature typical use of the fertile before getting unprotected (BBT) FABM period has out of bed vaginal sex Method (Trussell, passed. Sex observing for during 2009) can resume on an increase of fertile days the 4th day 0.2 to 0.5 until her next degrees C. monthly bleeding. Women track Prevents May have to their fertile be used with Sympto- pregnancy periods by Reported 98% caution after thermal by avoiding observing with typical an abortion, Method unprotected changes in the vaginal sex use (Manhart around cervical during et al, 2013) menarche or mucus (clear most fertile menopause, texture) , and in Effectiveness How it Method Description to prevent Comments works pregnancy body conditions temperature which may (slight increase body increase) and temperature. consistency of the cervix (softening). Women track their fertile May have to periods by be used with observing caution after changes in the Prevents an abortion, cervical pregnancy around Sympto- mucus (clear by avoiding menarche or thermal texture) , unprotected menopause, Method body vaginal sex and in temperature during conditions (slight most fertile which may increase) and increase body consistency of temperature. the cervix (softening). Traditional methods Traditional Methods Calendar Women The couple 91% with May need to delay method or monitor their prevents correct and or use with Traditional Methods rhythm pattern of pregnancy by consistent caution when method menstrual avoiding use. using drugs (such cycle over 6 unprotected as anxiolytics, months, vaginal sex antidepressants, subtracts 18 during the 1st NSAIDS, or from shortest and last certain antibiotics) cycle length estimated which may affect (estimated 1st fertile days, timing of fertile day) by abstaining 75% with ovulation. and subtracts or using a common 11 from condom. use longest cycle length (estimated last fertile day) 96% with One of the least correct and effective methods, Tries to keep consistent because proper sperm out of use timing of Withdrawal the woman's withdrawal is (coitus body, 73% as often difficult to interruptus) commonly preventing determine, leading used fertilization to the risk of ejaculating while inside the vagina. Intrauterine Devices (IUD) IUDs are placed by a healthcare provider through the vagina and cervix, into the uterus. The currently available IUDs are safe and effective. These devices include: ●Copper-containing IUD – The Copper-containing IUD remains effective for at least 10 years, but can be removed at any time. The Copper IUD does not contain any hormones. Some women have a heavier menstrual period or more cramps during their period while using a copper IUD. ●Levonorgestrel-releasing IUD – The levonorgestrel-releasing IUD (which is available in different doses) releases a hormone, levonorgestrel, which thickens the cervical mucus and thins the endometrium (the lining of the uterus). This IUD also decreases the amount you bleed during your period and decreases pain associated with periods. While IUDs can be removed at any time, they can be left in place for up to three or five years (depending on type of IUD chosen), but can be removed at any time, and is highly effective in preventing pregnancy. Some women stop having menstrual periods entirely; this effect is reversed when the IUD is removed. Birth Control Implant A single-rod progestin implant, Nexplanon, is available in the United States and elsewhere.
Load more

Recommended publications
  • Format (Sample) Dissertation
    Providers’ Knowledge, Perceptions and Views of Prescribing Long-Acting Reversible Contraception to Adolescents in a Southwest Community Health Center Item Type text; Electronic Dissertation Authors Schafer, Stephanie Lynne Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 02/10/2021 06:38:23 Link to Item http://hdl.handle.net/10150/626699 PROVIDERS’ KNOWLEDGE, PERCEPTIONS AND VIEWS OF PRESCRIBING LONG-ACTING REVERSIBLE CONTRACEPTION TO ADOLESCENTS IN A SOUTHWEST COMMUNITY HEALTH CENTER by Stephanie Lynne Schafer ________________________ Copyright © Stephanie Lynne Schafer 2017 A DNP Project Submitted to the Faculty of the COLLEGE OF NURSING In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF NURSING PRACTICE In the Graduate College THE UNIVERSITY OF ARIZONA 2 0 1 7 2 3 STATEMENT BY AUTHOR This DNP Project has been submitted in partial fulfillment of requirements for an advanced degree at The University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this DNP Project are allowable without special permission, provided that accurate acknowledgment of source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgment the proposed use of the material is in the interests of scholarship.
    [Show full text]
  • Assessing the Availability, Service Quality, and Price of Essential Medicines In
    Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Afghanistan Norio Kasahara A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Louis P. Garrison, Jr., Chair Joseph B. Babigumira Andy Stergachis Program Authorized to Offer Degree: Pharmaceutical Outcomes Research and Policy ©Copyright 2015 Norio Kasahara ii Table of Contents Abstract ................................................................................................................................................................................... ................................................................................................ ................................................................................................ .................................................................................. ............... vvv Acknowledgements ................................................................................................................................................................................... ................................................................................................ ................................................................................. ............ viiviivii Summary ................................................................................................................................................................................... ...............................................................................................
    [Show full text]
  • Injectable Birth Control May Raise HIV Infection Risk by 40%
    08 January 2018 Injectable birth control may raise HIV infection risk by 40% The intramuscular injectable contraceptive depot medroxyprogesterone acetate, or DMPA, may raise the risk for HIV infection by 40% in women, according to research published recently in Endocrine Reviews. Research indicates alternative contraception methods may help protect women. Professor Janet P. Hapgood, lead author of the review from the University of Cape Town’s (UCT) Department of Molecular and Cell Biology said: “To protect individual and public health, it is important to ensure women in areas with high rates of HIV infection have access to affordable and safe contraceptive options.” In the review, researchers noted that the injectable progestin contraceptive, DMPA, is the major form of hormonal contraceptive used in sub-Saharan Africa, which also has the highest worldwide HIV prevalence, particularly in young women. However, researchers also noted that DMPA may raise the risk for HIV infection by 40% in women. “The increased rate of HIV infection among women using DMPA contraceptive shots is likely due to multiple reasons, including decreases in immune function, and the protective barrier function of the female genital tract. Studying the biology of medroxyprogesterone acetate (MPA) helps us understand what may be driving the increased rate of HIV infection seen in human research,” remarked Hapgood. Increasing the availability of contraceptives that use a different form of progestin than the one found in DMPA could help reduce the risk of HIV transmission. Other forms of contraception, including combined oral contraceptives containing levonorgestrel or the injectable contraceptive norethisterone enanthate (NET-EN), were not associated with increased HIV infection risk.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Innovative Practices Among Publicly Operated Family Planning Centers
    Innovative Practices Among Publicly Operated Family Planning Centers COMPANION WORKBOOK Innovative Practices Among Publicly Operated Family Planning Centers COMPANION WORKBOOK Table of Contents CDPHE “Sustainability Coordinator” Job Description ................................................ 1 HCCMS Organizational History ............................................................................. 4 DHEC Regional Map ............................................................................................. 5 HCCMS Organizational Chart ............................................................................... 6 Sample Supply Requisition Sheet ............................................................................ 7 Sample Job Aid of Available Birth Control ............................................................... 9 Example Title X and FQHC Sliding Fee Scale ......................................................... 10 Example Guideline for Contraception ................................................................... 12 Example Contraception Wall Chart ....................................................................... 14 Example Clinical Guideline .................................................................................. 15 Sample Adolescent Services Policy ........................................................................ 17 South Carolina Campaign to Prevent Teen Pregnancy Mission Statement ........................................................................ 19 “One Key Question” Educational
    [Show full text]
  • The Effects of Hormonal Contraception on the Voice: History of Its Evolution in the Literature
    CARE OF THE PROFESSIONAL VOICE Robert T. Sataloff, Associate Editor The Effects of Hormonal Contraception on the Voice: History of its Evolution in the Literature Jennifer Rodney and Robert T. Sataloff [Modified from J. Rodney and R.T. Sataloff, “The Effects of Hormonal Contraception on the Voice: History of its Evolution in the Literature,” Journal of Voice 30, no. 6 (November 2016): 726–730; with permission.] INTRODUCTION: THE MENSTRUAL CYCLE AND THE VOICE The fluctuation of hormones in the menstrual cycle has significant effects on the voice.1 Singing teachers should be familiar with the vocal effects of Jennifer Rodney hormones and of hormonal medications such as oral contraceptives (birth control pills), especially in light of recent changes in their chemistry and effects. Vocal symptoms, known as dysphonia premenstrualis, accompany the better known symptoms of premenstrual syndrome (PMS) during the luteal phase of the menstrual cycle.2 The most common symptoms of dys- phonia premenstrualis are difficulty singing high notes, decreased flexibil- ity, huskiness, fuzziness, breathiness, decreased volume, difficulty bridging passaggios and intonation problems.3 Davis and Davis concluded that, on average, singers experience 33 general symptoms of PMS and 3 symptoms of dysphonia premenstrualis.4 Chae et al. showed that approximately 57% participants met the DSM IV criteria for PMS and also had acoustic evidence Robert T. Sataloff of dysphonia premenstrualis, whereas the PMS-negative group did not.5 The risk of vocal stress and possible damage during the premenstrual period led many European opera houses to offer singers contracts that included “grace days” during their premenstrual period. This accommodation is no longer followed in Europe and was never practiced generally in the United States.6 The mechanisms that cause these symptoms lie not just in the actions of the hormones themselves, but also in the cyclic fluctuation of hormone levels.
    [Show full text]
  • Contraception in Adolescents – Regulatory Considerations”
    “Contraception in adolescents – regulatory considerations” Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels „Master of Drug Regulatory Affairs“ der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von Dr. Julian Paesler aus Münster Bonn 2016 Betreuerin und 1. Referentin: Frau Dr. Ingrid Klingmann Zweiter Referent: Herr Prof. Dr. Niels Eckstein Acknowledgements I would like to express my sincere gratitude to Dr. Ingrid Klingmann for her friendly willingness to function as my “supervising tutor” and for the support and the motivating feedback she gave me during the preparation of this master thesis. Her comments and constructive suggestions were very helpful to me. Besides Dr. Ingrid Klingmann, I would like to thank Prof. Dr. Niels Eckstein for his support and the willingness to function as my “secondary tutor”. Special thanks are also due to my mother, who was willing to proofread this master thesis. I am really thankful for all the support she gave - and still gives – to me, which is way more than what could ever be mentioned here. Table of Contents Table of Contents List of Figures .......................................................................................................................... I List of Tables ......................................................................................................................... III List of Abbreviations ..............................................................................................................
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Vellena 75 micrograms / 20 micrograms Coated tablets Vellena 75 micrograms / 30 micrograms Coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients: Vellena: Each tablet contains 75 micrograms gestodene and 20 micrograms ethinylestradiol Vellena: Each tablet contains 75 micrograms gestodene and 30 micrograms ethinylestradiol Excipients with known effect: Vellena contains 38 mg lactose monohydrate and 20 mg sucrose For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Coated tablet. White, round, biconvex sugar coated tablets, both sides are without imprinting. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Oral contraception. The decision to prescribe Vellena should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Vellena compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4) 4.2 Posology and method of administration How to take Vellena The tablets should be taken in the order indicated on the package, every day at approximately the same time. One tablet per day should be taken for 21 days. Each subsequent pack should be started after a 7-day tablet-free interval during which time a withdrawal bleeding will occur. This bleeding usually starts on the 2nd or 3rd day after taking the last tablet, and may not stop until the next pack is started. How to start taking Vellena If no preceding hormonal contraceptive use in the past month Taking of the tablets should begin on the first day of the woman’s natural cycle (i.e.
    [Show full text]
  • Contraception - Update and Trends Rabe T J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Contraception - Update and Trends Rabe T J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 18-38 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Contraception – Update and Trends Contraception – Update and Trends* T. Rabe Fertility control in the future will focus on the improvement of existing methods (efficacy, side effects, easy use, duration of action, manufacturing process, costs), on new approaches (mode of action) bringing additional health benefits, and on new targets for nonhormonal contraception. Counselling of women in view to contraceptive choices based on the individual risk (e.
    [Show full text]
  • Full Text Article
    SJIF Impact Factor: 5.464 WORLD JOURNAL OF ADVANCE ISSN: 2457-0400 Nandi et al. World Journal of Advance HealthcareVolume: Research 5. HEALTHCARE RESEARCH Issue: 2. Page N. 307-318 Year: 2021 Review Article www.wjahr.com HUM DO HAMARE DO (WE TWO OUR’S TWO): THE MAIN THEME OF 21ST CENTURY *1Kushal Nandi, 1Saroni Saha, 1Dr. Dhrubo Jyoti Sen and 2Dr. Dhananjoy Saha 1Department of Pharmaceutical Chemistry, School of Pharmacy, Techno India University, Salt Lake City, Sector-V, EM-4, Kolkata-700091, West Bengal, India. 2Deputy Director, Directorate of Technical Education, Bikash Bhavan, Salt Lake City, Kolkata‒700091, West Bengal, India. Received date: 21 February 2021 Revised date: 11 March 2021 Accepted date: 31 March 2021 *Corresponding author: Kushal Nandi Department of Pharmaceutical Chemistry, School of Pharmacy, Techno India University, Salt Lake City, Sector-V, EM-4, Kolkata-700091, West Bengal, India. ABSTRACT Birth control, also known as contraception, anticonception, and fertility control, is a method or device used to prevent pregnancy. Birth control has been used since ancient times, but effective and safe methods of birth control only became available in the 20th century. Planning, making available, and using birth control is called family planning. Some cultures limit or discourage access to birth control because they consider it to be morally, religiously, or politically undesirable. The World Health Organization and United States Centers for Disease Control and Prevention provide guidance on the safety of birth control methods among women with specific medical conditions. The most effective methods of birth control are sterilization by means of vasectomy in males and tubal ligation in females, intrauterine devices (IUDs), and implantable birth control.
    [Show full text]
  • Study Protocol 1002-046 Amendment 1, 10 April 2017
    1. TITLE PAGE BEMPEDOIC ACID 1002-046 A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMPEDOIC ACID (ETC-1002) 180 MG COMPARED TO PLACEBO ADDED TO BACKGROUND LIPID-MODIFYING THERAPY IN PATIENTS WITH ELEVATED LDL-C WHO ARE STATIN INTOLERANT Study Phase: 3 IND Number: 106654 EudraCT Number: NA Indication: Treatment of hyperlipidemia Investigators: Approximately 71 sites located in North America Sponsor: Esperion Therapeutics, Inc. 3891 Ranchero Drive, Suite 150 Ann Arbor, MI 48108 Phone: 734-862-4840 Fax: 734-582-9720 Sponsor Contact: Medical Monitor: Version Date Original Protocol: 25 August 2016 Amendment 1: 10 April 2017 Confidentiality Statement THIS CONFIDENTIAL INFORMATION IS ABOUT AN INVESTIGATIONAL DRUG PROVIDED FOR THE EXCLUSIVE USE OF INVESTIGATORS OF THIS DRUG AND IS SUBJECT TO RECALL AT ANY TIME. THE INFORMATION IN THIS DOCUMENT MAY NOT BE DISCLOSED UNLESS SUCH DISCLOSURE IS REQUIRED BY FEDERAL OR STATE LAW OR REGULATIONS. SUBJECT TO THE FOREGOING, THIS INFORMATION MAY BE DISCLOSED ONLY TO THOSE PERSONS INVOLVED IN THE STUDY WHO HAVE NEED TO KNOW, WITH THE OBLIGATION NOT TO FURTHER DISSEMINATE THIS INFORMATION. THESE RESTRICTIONS ON DISCLOSURE WILL APPLY EQUALLY TO ALL FUTURE ORAL OR WRITTEN INFORMATION, SUPPLIED TO YOU BY ESPERION THERAPEUTICS, INC., WHICH IS DESIGNATED AS “PRIVILEGED” OR “CONFIDENTIAL. NCT number: NCT02988115 This NCT number has been applied to the document for purposes of posting on clinicaltrials.gov Confidential Page 1 of 153 Bempedoic Acid Esperion Therapeutics, Inc. Clinical Study Protocol 1002-046 Amendment 1, 10 April 2017 2. SYNOPSIS Name of Sponsor: Esperion Therapeutics, Inc.
    [Show full text]
  • The Effect of Hormonal Contraception on Antidepressant Use Evidence
    The effect of hormonal contraception on antidepressant use Evidence from a free hormonal birth control program Liselotte Seljom Master of Economic Theory and Econometrics UNIVERSITETET I OSLO May 2018 II The effect of hormonal contraception on antidepressant use: Evidence from a free hormonal birth control program Master’s Thesis written by Liselotte Seljom to obtain the degree of Master of Economic Theory and Econometrics Supervised by Professor Edwin Leuven at the Department of Economics at the University of Oslo © Liselotte Seljom 2018 The effect of hormonal contraception on antidepressant use: Evidence from a free hormonal birth control program Liselotte Seljom http://www.duo.uio.no/ Trykk: Reprosentralen, Universitetet i Oslo III IV Abstract The prevalence of depression among young people in Norway varies greatly between the genders. Adolescent girls report a three times higher experience of depressive symptoms as their peer boys. At the same time hormonal birth control is found to be associated with higher rates of depression. While suggesting it is unclear whether this relationship is causal. This thesis aims to analyze the effect of a subsidy on hormonal contraception consumption and the subsequent use of antidepressants. To do so, we will exploit a policy experiment that took place May 2008 until May 2009 where women in the age group 20-24-years old and living in a geographic limited part of Norway were offered free hormonal contraceptives. The analysis will use prescription data collected from the National Prescription Register “Reseptregisteret” and investigate the impact of hormonal contraceptive use on antidepressants, using a difference-in-differences framework. V Preface First and foremost, I would like to thank my supervisor Edwin Leuven for his excellent guidance through engaging knowledge and insightful comments.
    [Show full text]